Novo Nordisk's patents for weight-loss and obesity drugs upheld by U.S. Patent Office in challenge by Mylan Pharmaceuticals.
Bitcoin and cryptocurrencies decline due to bond yield surge and lackluster ETF debut. Market expectations and investor interest questioned.
RHI Magnesita announces the acquisition of P-D Refractories, enhancing production capabilities in alumina-based refractories and expanding into the process industries sector.
France's Minister for Small and Medium-Sized Enterprises plans antitrust review on meal-voucher commission rates, causing shares of issuers to drop. Response from companies and analysts' perspectives also discussed.
Cellectar Biosciences has been granted four patents for their proprietary drug delivery platform and lead drug for treating various cancers, including gliomas, lung cancer, melanoma, and more. The patents focus on targeting cancer stem cells, circulating tumor cells, and optimizing treatment effectiveness through fractionated dosing.
Bank of America's analysis reveals a shift in investor sentiment, with funds moving back into stocks and out of bonds. This article discusses the implications and raises caution about market disruptions.
Google is facing an antitrust trial with the Justice Department, shrouded in secrecy and potential consequences for its business practices.
Structure Therapeutics experiences a stock surge after positive weight-loss drug results and a $300 million private placement announcement. The company plans to advance drug development for type 2 diabetes and obesity through Phase 2b trials.
Fusion Antibodies reports a widened pretax loss for the first half of the year, with decreased revenue and concerns about future contracts. However, the company remains optimistic about a recovery in trading.
This article examines the challenges faced by electric vehicles in the political spotlight and explores possible solutions. It also highlights the environmental impact of the oil industry.